Skip to main content

Table 3 Resistance of gedatolisib in SW620/GEDA could be reversed by Ko143 and verapamil

From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Drug

IC50 ± SD

SW620/GEDA (μΜ)

Gedatolisib

5.323 ± 0.728

+ Verapamil (2 μM)

4.837 ± 0.521

+ Verapamil (5 μM)

2.433 ± 0.314*

+ Ko143 (2 μM)

1.442 ± 0.238*

+ Ko143 (5 μM)

0.713 ± 0.096*

Doxorubicin

0.353 ± 0.042

+ Verapamil (2 μM)

0.361 ± 0.037

+ Verapamil (5 μM)

0.174 ± 0.023*

Paclitaxel

0.767 ± 0.062

+ Verapamil (2 μM)

0.679 ± 0.065

+ Verapamil (5 μM)

0.411 ± 0.031*

Mitoxantrone

0.872 ± 0.076

+ Ko143 (2 μM)

0.341 ± 0.032*

+ Ko143 (5 μM)

0.172 ± 0.011*

Topotecan

2.517 ± 0.329

+ Ko143 (2 μM)

1.022 ± 0.016*

+ Ko143 (5 μM)

0.239 ± 0.036*

  1. *Presents when p value is < 0.05. Data was showed with mean ± SD, which is representative for at least three independent experiments
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us